Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV

Launched by UNIVERSITY OF SEVILLE · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how different medications used to treat hepatitis C virus (HCV) infections might interact with other drugs that patients commonly take. The researchers want to find out if patients taking two specific treatments, GLE/PIB or SOF/VEL, need to change their other medications due to potential interactions. Sometimes, these interactions can affect how well the HCV treatment works or lead to side effects. The goal is to see how often patients need to switch, stop, or change the dose of their other medications when starting HCV treatment.

To be eligible for this study, participants should be new patients starting treatment with either GLE/PIB or SOF/VEL and must also be using at least one other medication or recreational drug. The trial is open to all genders and is currently recruiting patients from specific hospitals in Spain. Participants can expect to have their medication use tracked closely before and during their HCV treatment to understand the impact of these drug interactions better. This information is crucial for improving treatment plans and patient safety in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Treatment naive patients who received therapy with GLE/PIB or SOF/VEL between April 1st, 2018, and July 1st, 2023, receiving ≥ 1 comedication or recreational drug.
• • 2. Attended in a hospital with electronic clinical records allowing access to all clinical visits and prescribed medications, both in all hospitals and in primary care institutions of the corresponding Spanish region during the study period.
• Exclusion Criteria:
• Patients who meet any of the following criteria will be excluded from the study:
• • 1. HCV treatment-experienced patients will be excluded.
• • 2. Patients without any comedication or recreational drug use
• • 3. Those who have attended private health care